German politicians condemn pharma firms' investment pullback

The German government’s planned health‑care reform, centered on the GKV contribution‑stabilisation law, has prompted pharmaceutical giants Eli Lilly and Boehringer Ingelheim to announce a drastic reduction of their investments in the country.

Green Party health‑policy spokesman Janosch Dahmen warned, “Die Politik darf sich von solchen Drückerkolonnen‑Methoden nicht einschüchtern lassen. Gesetze werden in einer Demokratie im Parlament gemacht – nicht in den Vorstandsetagen internationaler Pharmakonzerne.” Left Party MP Michael Arndt labelled the move “ein völlig unverhohlenen Erpressungsversuch aus reiner Profitgier”. Union spokesperson Simone Borchardt added, “Ich halte nichts davon, gesundheitspolitische Entscheidungen unter Drohkulissen zu treffen.”

The firms argue the new “dynamic manufacturer discount” – a price cut tied to statutory health‑insurance revenues and drug‑spending – threatens profitability, while politicians argue that the pull‑back jeopardises research, production and the competitiveness of Germany’s health‑care sector.